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Abstract
In our exploration of new biologically active chemical entities, we designed and synthesized a
novel class of antitumor agents, substituted 4-amino-7,8,9,10-tetrahydro-2H-benzo[h]chromen-2-
one (ATBO) analogs. We evaluated their cytotoxic activity against seven human tumor cell lines
from different tissues, and established preliminary structure-activity relationships (SAR). All
analogues, except 8, 9, and 25-27, displayed potent tumor cell growth inhibitory activity.
Especially, compounds 15 and 33 with a 4-methoxyphenyl group at position C-4 were extremely
potent with ED50 values of 0.008-0.064 μM and 0.035-0.32 μM, respectively. Compound 15 was
the most potent analog compared with structurally related neo-tanshinlactone (e.g., 1) and 4-
amino-2H-benzo[h]chromen-2-one (ABO, e.g., 4) analogs, and thus merits further exploration as
an anti-cancer drug candidate.
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One of the most challenging areas of research in both industry and academia is the discovery
and development of new medicines.1, 2 In 2009, 103 new drugs were approved by the
FDA's Center for Drug Evaluation and Research (CDER).3 Nineteen new molecular entities
(NMEs) and six biologics license applications (BLAs) were filed among these approvals.3
The pharmaceutical industry's demand for new leads with new scaffolds has never been
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greater.4 These facts prompted us to design and discover new biologically active chemical
entities.
Previously, our group successfully developed new cytotoxic chemical entities, including
neotanshinlactone (1, Figure 1) and its 4-ethyl analog 2,5, 6 for treating breast cancer, and
these compounds are now in extended preclinical study. Structural simplification and
optimization is a powerful tool for analog design and lead exploration. For example, this
strategy was applied to the natural product halichondrin B, a potent mitotic inhibitor, which
led to a new therapeutic medicine, eribulin mesylate.7 In our continuous exploration of new
chemical entities, we also designed and developed several additional series of novel
anticancer agents according to this strategy. These agents include 2-(furan-2-yl)
naphthalen-1-ol (FNO),8 6-phenyl-4H-furo[3,2-c]pyran-4-one (AFPO),9
tetrahydronaphthalene-1-ol (TNO),10 and 4-amino-2H-benzo[h]chromen-2-one (ABO, 3,
Figure 1)11 analogs. Lead compounds showed potent antitumor activity and different tumor
tissue type selectivity. Braccio et al first reported four compounds with the ABO scaffold
and their cytotoxic activity against Ehrlich ascites tumor cells.12 We also designed and
explored this scaffold based on our studies of neo-tanshinlactone analogs (1, 2). Compound
4 showed potent and broad antitumor activity compared with 1 and 2.11 Structure-activity
relationship (SAR) studies on 3 indicated that (1) secondary amine (R2 or R3 = H) is
preferred over tertiary amine (R2 and R3 ≠ H), (2) bulky groups are favored at R2/R3
position, (3) 3′-bromophenyl group can cause dramatic loss of potency, and (4) hydrogen is
better than an ethyl group at R1 position. Our prior studies also suggested that a non-
aromatic ring can greatly affect the antitumor activity and cancer cell line selectivity.10
Consequently, we have now designed scaffold 5 with a non-aromatic five- or six-membered
A-ring (Figure 1). Different amino (R2/R3) and A-ring (R1) substituents were incorporated
to establish SAR and identify potent analogs. This paper reports the design, synthesis, and
biological activity of 4-amino-7,8,9,10-tetrahydro-2H-benzo[h]chromen-2-one, (ATBO)
analogs.
All target compounds 8–27, 32, and 33 were synthesized from the related 4-hydroxy
compounds, 6, 28, and 29, respectively, according to the methods reported before (Scheme
1). Chlorides 7, 30, and 31 were synthesized by treatment of 6, 28, and 29, respectively, with
POCl3.11, 12 Various amino derivatives, 8–27, 32, and 33, were newly prepared by
substitution reactions of 7, 30, and 31 with different amines according to reported
procedures.12, 13
All synthesized analogs 8-27 and 32-33 were tested for in vitro cytotoxic activity against a
panel of human tumor cell lines according to previously published methods (Table 1).8,14,15
Cell lines included A549 (non small cell lung cancer), DU145 (prostate cancer cell line), KB
(nasopharyngeal carcinoma), KB-VIN (vincristine-resistant MDR KB subline), MDA-
MB-231 (estrogen receptor negative breast cancer), SK-BR-3 (estrogen receptor negative,
HER2 over-expressing breast cancer), and ZR-75-1 (estrogen receptor positive breast
cancer).
Regarding ATBO analogs with aliphatic R2/R3 amino substituents, 11 with a cyclohexyl
group showed greater activity than the methyl, propyl, and cyclopropyl derivatives 8-10.
Analog 10 with a cyclopropyl group displayed tumor cell line selectivity against KB, KB-
VIN, and ZR-75-1, while 8 and 9 showed greatly reduced or no activity against all tested
cell lines. These findings suggested that a cyclic group is better than a linear group for
cytotoxic activity, and a bulky amino group is favored. The tertiary amines 25-27 were not
active, regardless of cyclic or linear amino groups; thus, a secondary amine is crucial for
antitumor activity. The above results are consistent with our previous studies for ABO
analogs.10 Interestingly, 8 and 9 showed unique selectivity against ZR-75-1 compared with
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other cell lines tested, although the inhibitory potency was only moderate. In addition, 11
with a cyclohexyl group showed similar potency to 12 with a phenyl group, which indicated
that aromaticity of the amino substituent is not an essential factor.
Regarding aromatic R2/R3 substitutents, we explored different groups at the 2’, 3’, and 4’
positions. Generally, all aromatic derivatives 12–24 showed significant cytotoxicity against
the human tumor cell lines tested. Among them, 4′-MeO 15 was the most potent analog
against all tested tumor cell lines (ED50 values of 0.008-0.064 μM). It was two- to three-fold
more potent than the related ABO analog 4 against all cell lines, except ZR-75-1.
Importantly, 15 also exhibited the highest cytotoxicity against MDA-MB-231 (ER negative
breast cancer) compared with other cell lines. Analogs 10-13, 19, and 23-24 were less potent
against MDA-MB-231 and 14, 16, 21-22 were less potent against both MDA-MB-231 and
ZR-75-1 compared with other tested cell lines, which indicated different cancer cell line
selectivity among ATBO analogs.
We further investigated the effect of ring-A. Analogs 15 and 32, with an unsubstituted six
and five-membered ring, respectively, as well as analog 33, with a six-membered ring-A
with gem-dimethyl substitution, displayed significant inhibition against all tested human
tumor cell lines, but different selectivity against tumor cell lines from different tissues.
Against KB, KB-VIN, A549, DU145, and SKBR-3, 15 and 33 were at least twofold more
potent than 32. Against ZR-75-1 and MDA-MB-231, 15 (ED50 0.024 and 0.008 μM,
respectively) showed much higher activity as compared with 32 and 33. These results
together with our previous findings indicated that a non-aromatic ring-A may lead to
changes in both potency and cancer cell line selectivity of certain analogs. The size and
identity of ring-A substituents are also important factors.
In conclusion, our structural modification and optimization resulted in a novel class of in
vitro anti-cancer agents, ATBO. The results indicated that the non-aromatic ring-A of 5 is
critical to both potency and cancer cell line selectivity. Based on this study, the preliminary
SAR findings for the ATBO class were similar to those with ABO analogs. (1) Secondary
amine (R2 or R3 = H) is preferred over tertiary amine (R2 and R3 ≠ H), (2) bulky groups are
favored at R2/R3 position, (3) aromaticity is not required at R2/R3 position, and (4) non-
aromatic ring-A can increase potency and cancer cell line selectivity for certain analogs,
such as 15. Compound 15 was the most potent analog (ED50 values of 0.008-0.064 μM)
among all ABO and ATBO derivatives, and thus, is a promising new lead compound for
further development toward a potential clinical trials candidate.
Acknowledgments
This work was supported by NIH grant CA-17625 from the National Cancer Institute, awarded to K.H. Lee.
References and notes
1. Bleicher Konrad H, Bohm H-J, Muller K, Alanine Alexander I. Hit and lead generation: beyond
high-throughput screening. Nat Rev Drug Discov 2003;2:369–78. [PubMed: 12750740]
2. Vallance P, Williams P, Dollery C. The future is much closer collaboration between the
pharmaceutical industry and academic medical centers. Clin Pharmacol Ther 87:525–7. [PubMed:
20407455]
3. Hughes B. FDA drug approvals. Nat Rev Drug Discov 2009;9:89–92. [PubMed: 20118952]
4. Crommelin D, Stolk P, Besancon L, Shah V, Midha K, Leufkens H. Pharmaceutical sciences in
2020. Nat Rev Drug Discov 9:99–100. [PubMed: 20118959]
5. Wang X, Bastow KF, Sun CM, Lin YL, Yu HJ, Don MJ, Wu TS, Nakamura S, Lee KH. Antitumor
Agents. 239. Isolation, structure elucidation, total synthesis, and anti-breast cancer activity of neo-
tanshinlactone from Salvia miltiorrhiza. J Med Chem 2004;47:5816–9. [PubMed: 15509181]
Dong et al. Page 3













6. Wang X, Nakagawa-Goto K, Bastow KF, Don MJ, Lin YL, Wu TS, Lee KH. Antitumor agents.
254. Synthesis and biological evaluation of novel neo-tanshinlactone analogues as potent anti-breast
cancer agents. J Med Chem 2006;49:5631–4. [PubMed: 16942038]
7. Kim DS, Dong CG, Kim JT, Guo H, Huang J, Tiseni PS, Kishi Y. New syntheses of E7389 C14-
C35 and halichondrin C14-C38 building blocks: double-inversion approach. J Am Chem Soc
2009;131:15636–41. [PubMed: 19807076]
8. Dong Y, Shi Q, Liu Y-N, Wang X, Bastow KF, Lee K-H. Antitumor Agents. 266. Design,
Synthesis, and Biological Evaluation of Novel 2-(Furan-2-yl)naphthalen-1-ol Derivatives as Potent
and Selective Antibreast Cancer Agents. J. Med. Chem 2009;52:3586–3590. [PubMed: 19425534]
9. Dong Y, Shi Q, Nakagawa-Goto K, Wu P-C, Morris-Natschke SL, Brossi A, Bastow KF, Lang J-Y,
Hung M-C, Lee K-H. Antitumor agents 270. Novel substituted 6-phenyl-4H-furo[3,2-c]pyran-4-one
derivatives as potent and highly selective anti-breast cancer agents. Bioorg. Med. Chem 18:803–
808. [PubMed: 20034799]
10. Dong Y, Shi Q, Nakagawa-Goto K, Wu PC, Bastow KF, Morris-Natschke SL, Lee KH. Antitumor
agents 269. Non-aromatic ring-A neotanshinlactone analog, TNO, as a new class of potent
antitumor agents. Bioorg Med Chem Lett 2009;19:6289–92. [PubMed: 19819136]
11. Yizhou Dong KN-G, Lai Chin-Yu, Morris-Natschke Susan L. Bastow Kenneth F. Lee Kuo-
Hsiung. Antitumor Agents 278. 4-Amino-2H-benzo[h]chromen-2-one (ABO) Analogs as Potent In
Vitro Anticancer Agents. Bioorganic & Medicinal Chemistry Letters. 2010 in press.
12. Di Braccio M, Grossi G, Roma G, Marzano C, Baccichetti F, Simonato M, Bordin F. Pyran
derivatives. Part XXI. Antiproliferative and cytotoxic properties of novel N-substituted 4-
aminocoumarins, their benzo-fused derivatives, and some related 2-aminochromones. Farmaco
2003;58:1083–1097. [PubMed: 14572859]
13. Alberola A, Alvaro R, Ortega AG, Sadaba ML, Sanudo MC. Synthesis of [1]benzopyrano[4,3-
b]pyrrol-4(1H)-ones from N(alpha )-(2-oxo-2H-1-benzopyran-4-yl)weinreb alpha -aminoamides.
Tetrahedron 1999;55:13211–13224.
14. Solubility of 12-14 and 16-18 in DMSO is not very great. Work is ongoing to solve the solubility
issue and results will be reported in due course.
15. Spectroscopic data. 4-(methylamino)-7,8,9,10-tetrahydro-2H-benzo[h]chromen-2-one (8): 1H
NMR (400 MHz, CDCl3): δ 7.16 (d, 1H, J = 8.4 Hz, Ar-H), 6.96 (d, 1H, J = 8.4 Hz, Ar-H), 5.28
(s, 2H, NH & 3-H), 3.00 (d, 3H, J = 4.8 Hz, NCH3), 2.90 (t, 2H, J = 6.0 Hz, 10-H), 2.83 (t, 2H, J =
6.0 Hz, 7-H), 1.82 (m, 4H, 8 & 9-H). MS m/z 228 (M+-1). 4-(propylamino)-7,8,9,10-
tetrahydro-2H-benzo[h]chromen-2-one (9): 1H NMR (400 MHz, CDCl3): δ 7.18 (d, 1H, J = 8.0
Hz, Ar-H), 6.96 (d, 1H, J = 8.0 Hz, Ar-H), 5.28 (s, 1H, 3-H), 5.19 (br s, 1H, NH), 3.22 (q, 2H, J =
5.2 Hz, NCH2), 2.90 (t, 2H, J = 6.0 Hz, 10-H), 2.82 (t, 2H, J = 6.0 Hz, 7-H), 1.78 (m, 6H, 8, 9 &
2’-H), 1.04 (t, 3H, J = 7.2 Hz, 3’-H). MS m/z 258 (M++1). 4-(cyclopropylamino)-7,8,9,10-
tetrahydro-2H-benzo[h]chromen-2-one (10): 1H NMR (400 MHz, CDCl3): δ 7.10 (d, 1H, J = 8.4
Hz, Ar-H), 6.94 (d, 1H, J = 8.0 Hz, Ar-H), 5.72 (s, 1H, 3-H), 5.41 (br s, 1H, NH), 2.90 (t, 2H, J =
5.6 Hz, 10-H ), 2.83 (t, 2H, J = 5.6 Hz, 7-H), 2.58 (m, 1H, NCH), 1.83 (m, 4H, 8 & 9-H), 0.91 (dd,
2H, J = 5.6, 5.2 Hz, NCHCH2), 0.68 (dd, 2H, J = 5.2, 4.4 Hz, NCHCH2). MS m/z 254 (M+-1). 4-
(cyclohexylamino)-7,8,9,10-tetrahydro-2H-benzo[h]chromen-2-one (11): 1H NMR (400 MHz,
CDCl3): δ 7.15 (d, 1H, J = 8.0 Hz, Ar-H), 6.95 (d, 1H, J = 8.4 Hz, Ar-H), 5.31 (s, 1H, 3-H), 5.01
(d, 1H, J = 5.6 Hz, NH), 3.40 (m, 1H, 1’-H), 2.90 (t, 2H, J = 6.0 Hz, 10-H), 2.81 (t, 2H, J = 6.0
Hz, 7-H), 2.12 (m, 2H, 2’ & 6’-H), 1.78 (m, 6H, 8, 9 & 2’ & 6’-H), 1.28 (m, 6H, 3’ & 4’& 5’-H).
MS m/z 298 (M++1). 4-phenylamino-7,8,9,10-tetrahydro-2H-benzo[h]chromen-2-one (12): 1H
NMR (400 MHz, DMSO-d6): δ 9.20 (br s, 1H, NH), 7.96 (d, 1H, J = 8.2 Hz, Ar-H), 7.48 (dd, 1H,
J = 8.2 and 7.4 Hz, Ar-H), 7.36 (d, 1H, J = 8.2 Hz, Ar-H), 7.36 (d, 1H, J = 7.4 Hz, Ar-H), 7.28
(dd, 1H, J = 7.4 and 7.2 Hz, Ar-H), 7.12 (d, 1H, J = 8.2 Hz, Ar-H), 5.27 (s, 1H, 3-H), 2.86-2.74
(m, 4H, 7 &10-H), 1.85-1.72 (m, 4H, 8 & 9-H). MS m/z 292 (M++1). 4-[(4’-
methylphenyl)amino]-7,8,9,10-tetrahydro-2H-benzo[h]chromen-2-one (13): 1H NMR (400 MHz,
DMSO-d6): δ 9.14 (br s, 1H, NH), 7.95 (d, 1H, J = 8.3 Hz, Ar-H), 7.28 (d, 2H, J = 8.2 Hz, Ar-H),
7.23 (d, 2H, J = 8.2 Hz, Ar-H), 5.19 (s, 1H, 3-H), 2.86-2.74 (m, 4H, 7 &10-H), 2.34 (s, 3H, Ar-
CH3), 1.84-1.71 (m, 4H, 8 & 9-H). MS m/z 306 (M++1). 4-[(4’-ethylphenyl)amino]-7,8,9,10-
tetrahydro-2H-benzo[h]chromen-2-one (14): 1H NMR (400 MHz, DMSO-d6): δ 9.14 (br s, 1H,
NH), 7.95 (d, 1H, J = 8.4 Hz, Ar-H), 7.31 (d, 2H, J = 8.4 Hz, Ar-H), 7.25 (d, 2H, J = 8.4 Hz, Ar-
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= 7.5 Hz, Ar-CH2CH3), 1.84-1.72 (m, 4H, 8 & 9-H), 1.21 (t, 3H, J = 7.5 Hz, Ar-CH2CH3). MS m/
z 320 (M++1). 4-((4’-methoxyphenyl)amino)-7,8,9,10-tetrahydro-2H-benzo[h]chromen-2-one
(15): 1H NMR (400 MHz, DMSO-d6): δ 9.09 (br s, 1H, NH), 7.94 (d, 1H, J = 8.8 Hz, Ar-H), 7.27
(d, 2H, J = 8.0 Hz, Ar-H), 7.10 (d, 1H, J = 8.0 Hz, Ar-H), 7.04 (d, 2H, J = 8.0 Hz, Ar-H), 5.05 (s,
1H, 3-H), 3.79 (s, 3H, OCH3), 2.82 (t, 2H, J = 5.6 Hz, 10-H), 2.76 (t, 2H, J = 5.6 Hz, 7-H), 1.78
(m, 4H, 8 & 9-H). MS m/z 320 (M+-1). 4-[(4’-fluorophenyl)amino]-7,8,9,10-tetrahydro-2H-
benzo[h]chromen-2-one (16): 1H NMR (400 MHz, DMSO-d6): δ 9.18 (br s, 1H, NH), 7.93 (d, 1H,
J = 8.2 Hz, Ar-H), 7.42-7.36 (m, 2H, Ar-H), 7.35-7.28 (m, 2H, Ar-H), 7.12 (d, 1H, J = 8.2 Hz, Ar-
H), 5.16 (s, 1H, 3-H), 2.86-2.73 (m, 4H, 7 &10-H), 1.85-1.71 (m, 4H, 8 & 9-H). MS m/z 310
(M++1). 4-[(4’-bromophenyl)amino]-7,8,9,10-tetrahydro-2H-benzo[h]chromen-2-one (17): 1H
NMR (400 MHz, DMSO-d6): δ 9.21 (br s, 1H, NH), 7.92 (d, 1H, J = 8.3 Hz, Ar-H), 7.68-7.62 (m,
2H, Ar-H), 7.36-7.31 (m, 2H, Ar-H), 7.12 (d, 1H, J = 8.3 Hz, Ar-H), 5.34 (s, 1H, 3-H), 2.86-2.74
(m, 4H, 7 &10-H), 1.85-1.72 (m, 4H, 8 & 9-H). MS m/z 368 and 370 (1:1, M+-1). 4-[(2’-
methylphenyl)amino]-7,8,9,10-tetrahydro-2H-benzo[h]chromen-2-one (18): 1H NMR (400 MHz,
DMSO-d6): δ 9.10 (br s, 1H, NH), 7.96 (d, 1H, J = 8.2 Hz, Ar-H), 7.44-7.39 (m, 1H, Ar-H),
7.36-7.31 (m, 2H, Ar-H), 7.29-7.24 (m, 1H, Ar-H), 7.12 (d, 1H, J = 8.2 Hz, Ar-H), 4.54 (s, 1H, 3-
H), 2.86-2.74 (m, 4H, 7 &10-H), 2.18 (s, 3H, Ar-CH3), 1.85-1.72 (m, 4H, 8 & 9-H). MS m/z 306
(M++1). 4-[(2’-methoxyphenyl)amino]-7,8,9,10-tetrahydro-2H-benzo[h]chromen-2-one (19): 1H
NMR (400 MHz, DMSO-d6): δ 8.90 (br s, 1H, NH), 7.96 (d, 1H, J = 8.2 Hz, Ar-H), 7.42-7.34 (m,
1H, Ar-H), 7.32-7.26 (m, 1H, Ar-H), 7.20 (d, 1H, J = 8.2 Hz, Ar-H), 7.10 (d, 1H, J = 8.2 Hz, Ar-
H), 7.09-7.05 (m, 1H, Ar-H), 4.68 (s, 1H, 3-H), 3.79 (s, 3H, OCH3), 2.96-2.72 (m, 4H, 7 &10-H),
1.86-1.70 (m, 4H, 8 & 9-H). MS m/z 322 (M++1). 4-[(2’-bromophenyl)amino]-7,8,9,10-
tetrahydro-2H-benzo[h]chromen-2-one (20): 1H NMR (400 MHz, DMSO-d6): δ 9.21 (br s, 1H,
NH), 7.98-7.90 (m, 1H, Ar-H), 7.70-7.62 (m, 1H, Ar-H), 7.50-7.24 (m, 3H, Ar-H), 7.12 (d, 1H, J
= 8.3 Hz, Ar-H), 5.35 (s, 1H, 3-H), 2.86-2.74 (m, 4H, 7 &10-H), 1.85-1.72 (m, 4H, 8 & 9-H). MS
m/z 368 and 370 (1:1, M+-1). 4-[(3’-methylphenyl)amino]-7,8,9,10-tetrahydro-2H-
benzo[h]chromen-2-one (21): 1H NMR (400 MHz, DMSO-d6): δ 9.15 (br s, 1H, NH), 7.95 (d, 1H,
J = 8.3 Hz, Ar-H), 7.36 (t, 1H, J = 7.7 Hz, Ar-H), 7.19-7.08 (m, 3H, Ar-H), 5.26 (s, 1H, 3-H),
2.86-2.74 (m, 4H, 7 &10-H), 2.36 (s, 3H, Ar-CH3), 1.85-1.72 (m, 4H, 8 & 9-H). MS m/z 306
(M++1). 4-[(3’-methoxyphenyl)amino]-7,8,9,10-tetrahydro-2H-benzo[h]chromen-2-one (22): 1H
NMR (400 MHz, DMSO-d6): δ 9.16 (br s, 1H, NH), 7.94 (d, 1H, J = 8.4 Hz, Ar-H), 7.38 (t, 1H, J
= 8.1 Hz, Ar-H), 7.11 (d, 1H, J = 8.4 Hz, Ar-H), 6.98-6.92 (m, 1H, Ar-H), 6.92-6.89 (m, 1H, Ar-
H), 6.85 (dd, 1H, J = 8.1 and 2.5 Hz, Ar-H), 5.35 (s, 1H, 3-H), 3.79 (s, 3H, OCH3), 2.86-2.74 (m,
4H, 7 &10-H), 1.85-1.72 (m, 4H, 8 & 9-H). MS m/z 322 (M++1). 4-[(3’-
bromophenyl)amino]-7,8,9,10-tetrahydro-2H-benzo[h]chromen-2-one (23): 1H NMR (400 MHz,
DMSO-d6): δ 9.24 (br s, 1H, NH), 7.91 (d, 1H, J = 8.2 Hz, Ar-H), 7.48-7.59-7.56 (m, 1H, Ar-H),
7.40 (m, 3H, Ar-H), 7.13 (d, 1H, J = 8.2 Hz, Ar-H), 5.39 (s, 1H, 3-H), 2.86-2.74 (m, 4H, 7 &10-
H), 1.85-1.72 (m, 4H, 8 & 9-H). MS m/z 368 and 370 (1:1, M+-1). 4-(naphthalen-1-
ylamino)-7,8,9,10-tetrahydro-2H-benzo[h]chromen-2-one (24): 1H NMR (400 MHz, DMSO-d6):
δ 9.54 (br s, 1H, NH), 8.13 (d, 1H, J = 8.2 Hz, Ar-H), 8.05 (d, 1H, J = 7.4 Hz, Ar-H), 8.01 (d, 1H,
J = 8.2 Hz, Ar-H), 7.81 (d, 1H, J = 8.2 Hz, Ar-H), 7.65 (dd, 1H, J = 8.2 and 7.4 Hz, Ar-H),
7.64-7.53 (m, 3H, Ar-H), 7.18 (d, 1H, J = 8.2 Hz, Ar-H), 4.50 (s, 1H, 3-H), 2.90-2.75 (m, 4H, 7
&10-H), 1.86-1.74 (m, 4H, 8 & 9-H) . MS m/z 342 (M++1). 4-(dipropylamino)-7,8,9,10-
tetrahydro-2H-benzo[h]chromen-2-one (25): 1H NMR (400 MHz, CDCl3): δ 7.37 (d, 1H, J = 8.4
Hz, Ar-H), 6.94 (d, 1H, J = 8.4 Hz, Ar-H), 5.59 (s, 1H, 3-H), 3.27 (t, 4H, J = 6.0 Hz, N(CH2) 2),
2.91 (t, 2H, J = 5.6 Hz, 10-H), 2.82 (t, 2H, J = 5.6 Hz, 7-H), 1.83 (m, 4H, 8 & 9-H), 1.68 (m, 4H,
N(CH2 CH2 CH3) 2), 0.90 (t, 6H, J = 7.6 Hz, N(CH2 CH2 CH3) 2). MS m/z 300 (M++1). 4-
(piperidin-1-yl)-7,8,9,10-tetrahydro-2H-benzo[h]chromen-2-one (26): 1H NMR (400 MHz,
CDCl3): δ 7.32 (d, 1H, J = 8.0 Hz, Ar-H), 6.94 (d, 1H, J = 8.4 Hz, Ar-H), 5.64 (s, 1H, 3-H), 3.20
(t, 4H, J = 5.6 Hz, N(CH2) 2), 2.90 (t, 2H, J = 5.6 Hz, 10-H), 2.82 (t, 2H, J = 5.6 Hz, 7-H), 1.81
(m, 8H, 8 & 9 & 3’ & 5’-H), 1.72 (m, 2H, NCH2 CH2 CH2). MS m/z 284 (M++1). 4-
morpholino-7,8,9,10-tetrahydro-2H-benzo[h]chromen-2-one (27): 1H NMR (400 MHz, CDCl3): δ
7.32 (d, 1H, J = 8.4 Hz, Ar-H), 6.96 (d, 1H, J = 8.4 Hz, Ar-H), 5.69 (s, 1H, 3-H), 3.92 (t, 4H, J =
4.8 Hz, O(CH2) 2), 3.23 (t, 4H, J = 4.8 Hz, N(CH2) 2), 2.90 (t, 2H, J = 5.6 Hz, 10-H), 2.83 (t, 2H,
J = 5.6 Hz, 7-H), 1.83 (m, 4H, 8 & 9-H). MS m/z 286 (M++1). 4-((4’-methoxyphenyl)amino)-8,9-
dihydrocyclopenta[h]chromen-2(7H)-one (32): 1H NMR (400 MHz, DMSO-d6): δ 9.13 (br s, 1H,
NH), 8.00 (d, 1H, J = 8.0 Hz, Ar-H), 7.27 (m, 3H, Ar-H), 7.04 (d, 2H, J = 8.4 Hz, Ar-H), 5.04 (s,
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1H, 3-H), 3.79 (s, 3H, OCH3), 3.00 (m, 4H, 7 & 9-H), 2.13 (m, 2H, 8-H). MS m/z 306 (M+-1). 4-
((4’-methoxyphenyl)amino)-7,7-dimethyl-7,8,9,10-tetrahydro-2H-benzo[h]chromen-2-one
(33): 1H NMR (400 MHz, DMSO-d6): δ 9.10 (br s, 1H, NH), 8.00 (d, 1H, J = 8.4 Hz, Ar-H), 7.41
(d, 1H, J = 8.4 Hz, Ar-H), 7.25 (d, 2H, J = 8.4 Hz, Ar-H), 7.04 (d, 2H, J = 8.8 Hz, Ar-H), 5.04 (s,
1H, 3-H), 3.79 (s, 3H, OCH3), 2.76 (t, 2H, J = 6.0 Hz, 10-H), 1.79 (m, 2H, 9-H), 1.65 (m, 2H, 8-
H), 1.30 (s, 6H, (CH3)2). MS m/z 348 (M+-1).
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Structures of neo-tanshinlactone (1), 4-ethyl neo-tanshinlactone (2), previously reported
scaffold 3 and its analog 4, and newly designed scaffold 5
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Reagents and conditions: (a) POCl3, Et3N, reflux, 1h; (b) aliphatic amines, EtOH, reflux, 2h;
(c) aromatic amines, ethylene glycol, 160 °C, 1h.
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